Literature DB >> 17082571

Cutting edge: the phosphoinositide 3-kinase p110 delta is critical for the function of CD4+CD25+Foxp3+ regulatory T cells.

Daniel T Patton1, Oliver A Garden, Wayne P Pearce, Louise E Clough, Clare R Monk, Eva Leung, Wendy C Rowan, Sara Sancho, Lucy S K Walker, Bart Vanhaesebroeck, Klaus Okkenhaug.   

Abstract

CD4+CD25+Foxp3+ regulatory T cells (Tregs) contribute to the maintenance of peripheral tolerance by inhibiting the expansion and function of conventional T cells. Treg development and homeostasis are regulated by the Ag receptor, costimulatory receptors such as CD28 and CTLA-4, and cytokines such as IL-2, IL-10, and TGF-beta. Here we show that the proportions of Tregs in the spleen and lymph nodes of mice with inactive p110delta PI3K (p110deltaD910A/D910A) are reduced despite enhanced Treg selection in the thymus. p110deltaD910A/D910A CD4+CD25+Foxp3+ Tregs showed attenuated suppressor function in vitro and failed to secrete IL-10. In adoptive transfer experiments, p110deltaD910A/D910A T cells failed to protect against experimental colitis. The identification of p110delta as an intracellular signaling protein that regulates the activity of CD4+CD25+Foxp3+ Tregs may facilitate the further elucidation of the molecular mechanisms responsible for Treg-mediated suppression.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17082571     DOI: 10.4049/jimmunol.177.10.6598

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  132 in total

Review 1.  The B-cell receptor signaling pathway as a therapeutic target in CLL.

Authors:  Jennifer A Woyach; Amy J Johnson; John C Byrd
Journal:  Blood       Date:  2012-06-19       Impact factor: 22.113

Review 2.  Interleukin-2 receptor signaling: at the interface between tolerance and immunity.

Authors:  Thomas R Malek; Iris Castro
Journal:  Immunity       Date:  2010-08-27       Impact factor: 31.745

3.  Foxo proteins cooperatively control the differentiation of Foxp3+ regulatory T cells.

Authors:  Weiming Ouyang; Omar Beckett; Qian Ma; Ji-hye Paik; Ronald A DePinho; Ming O Li
Journal:  Nat Immunol       Date:  2010-05-13       Impact factor: 25.606

4.  T regulatory cells maintain intestinal homeostasis by suppressing γδ T cells.

Authors:  Sung-Gyoo Park; Ramkumar Mathur; Meixiao Long; Namiko Hosh; Liming Hao; Matthew S Hayden; Sankar Ghosh
Journal:  Immunity       Date:  2010-11-11       Impact factor: 31.745

5.  Biased binding of class IA phosphatidyl inositol 3-kinase subunits to inducible costimulator (CD278).

Authors:  Yenny Y Acosta; Maria Paz Zafra; Gloria Ojeda; Ilaria Seren Bernardone; Umberto Dianzani; Pilar Portolés; Jose M Rojo
Journal:  Cell Mol Life Sci       Date:  2010-12-28       Impact factor: 9.261

6.  Lineage extrinsic and intrinsic control of immunoregulatory cell numbers by SHIP.

Authors:  Michelle M Collazo; Kim H T Paraiso; Mi-Young Park; Amy L Hazen; William G Kerr
Journal:  Eur J Immunol       Date:  2012-07       Impact factor: 5.532

Review 7.  Genetically engineered mouse models for studying inflammatory bowel disease.

Authors:  Atsushi Mizoguchi; Takahito Takeuchi; Hidetomo Himuro; Toshiyuki Okada; Emiko Mizoguchi
Journal:  J Pathol       Date:  2015-11-14       Impact factor: 7.996

8.  The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL.

Authors:  K Balakrishnan; M Peluso; M Fu; N Y Rosin; J A Burger; W G Wierda; M J Keating; K Faia; S O'Brien; J L Kutok; V Gandhi
Journal:  Leukemia       Date:  2015-04-28       Impact factor: 11.528

9.  PI3K p110delta regulates T-cell cytokine production during primary and secondary immune responses in mice and humans.

Authors:  Dalya R Soond; Elisa Bjørgo; Kristine Moltu; Verity Q Dale; Daniel T Patton; Knut Martin Torgersen; Fiona Galleway; Breda Twomey; Jonathan Clark; J S Hill Gaston; Kjetil Taskén; Peter Bunyard; Klaus Okkenhaug
Journal:  Blood       Date:  2010-01-15       Impact factor: 22.113

10.  PI3K p110δ inactivation antagonizes chronic lymphocytic leukemia and reverses T cell immune suppression.

Authors:  Shuai Dong; Bonnie K Harrington; Eileen Y Hu; Joseph T Greene; Amy M Lehman; Minh Tran; Ronni L Wasmuth; Meixiao Long; Natarajan Muthusamy; Jennifer R Brown; Amy J Johnson; John C Byrd
Journal:  J Clin Invest       Date:  2018-11-19       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.